Article Figures & Data
Figures
- Figure 1
Impact of 5-AZA-CdR on CTA expression in sarcoma cells and recognition by CTLs. (A) RT-PCR analysis of untreated tumor cells or cells treated with 5-AZA-CdR. (B) Antigen recognition of SW 872 sarcoma cells by CTA-specific CTLs in the absence (white bars) or presence (dashed bars) of 1 µg/ml of the corresponding peptide.
- Figure 2
Expression of NY-ESO-1 antigen in a patient with synovial sarcoma. The expression of NY-ESO-1 in a tumor specimen from patient SS case 2 was assessed using monoclonal antibody ES121. For comparison, ES121-specific staining is shown for spermatogonia/primary spermatocytes in the periphery of seminiferous tubles.
- Figure 3
Spontaneous immune response to NY-ESO-1 antigen in SS case 2. (A) The presence of NY-ESO-1-specific circulating antibodies was assessed by ELISA using serial serum dilutions. (B) NY-ESO-1-specific CTLs were assessed among circulating CD8+ T lymphocytes, 1 wk after in vitro stimulation with peptide NY-ESO-1157-165, using fluorescent soluble HLA-A2/NY-ESO-1 peptide multimers and anti-CD8 mAb.
Tables
- Table 2
Comparison of NY-ESO-1 expression in sarcoma tumors as assessed by PCR or IHC.
Histological subtype Case no. NY-ESO-1 PCR a IHC b Gastrointestinal stromal tumor 1 +++ 3/pos 2 - 0/neg 3 + 2/pos 4 - 0/neg 5 - 0/neg Synovial sarcoma 1 +++ 2-3/pos 2 +++ 3/pos Uterine leiomyosarcoma 1 + 1/neg 2 - 1/neg 3 - 0/neg 4 + 2/pos 5 +++ 3/pos Leiomyosarcoma 1 - 0/neg 2 - 1/neg 3 - 0/neg 4 - 1/neg 5 - 0/neg 6 - 0/neg 7 - 1/neg Angiosarcoma 1 + 1/neg 2 ++ 2/pos 3 - 1/neg Malignant fibrous histiocytoma 1 ++ 2/pos 2 - 1/neg 3 - 1/neg 4 - 1/neg 5 - 0/neg Liposarcoma 1 - 1/neg 2 +++ 3/pos 3 - 0/neg 4 - 0/neg 5 - 0/neg 6 - nd Osteosarcoma 1 - 0/neg Chondrosarcoma 1 + 0/neg 2 + 1/neg aNY-ESO-1 expression at the RNA level was assessed by semiquantitative RT-PCR. bNY-ESO-1 expression at the protein level was assessed by IHC using monoclonal antibody ES121 to NY-ESO-1. Scoring: 0, no positive cells; 1, rare and scattered positive cells; 2, < or = 50% positive cells; 3, >50% positive cells; nd, not done. Interpretation: pos, positive; neg, negative.
- Table 3
MHC class I and HLA-A2 expression in tumor cell lines.
Cell line HLA-A2 typing MHC class I expression a HLA-A2 expression b Isotype control - IFN-gamma + IFN-gamma Isotype control - IFN-gamma + IFN-gamma SK-ES-1 + 5 20 325 2 6 134 SK-LMS-1 + 7 184 543 6 107 551 SK-UT-1 + 6 263 412 4 5 8 SW 872 + 6 84 121 5 187 630 Saos-2 + 6 118 150 4 84 150 HOS + 11 183 230 7 244 558 MES-SA - 6 28 245 3 5 6 HT-1080 - 5 36 330 4 8 8 SK-MEL-37 + 4 78 158 4 38 63 Mel 275 + 5 76 * c 4 75 * c aMHC-class-I expression was assessed by staining with mAb W6/32. The mean fluorescence intensity is reported. bHLA-A2 expression was assessed by staining with mAb BB7.2. The mean fluorescence intensity is reported. cCells died upon treatment with IFN-gamma.
- Table 4
MHC class I expression in sarcoma tumors.
Histological subtype Case no. MHC class I expression W6/32 a Interpretation b Gastrointestinal stromal tumor 1 C1 + 2 C2 + 3 A1 - 4 B1 + 5 C2 + Synovial sarcoma 1 A0 - Uterine leiomyosarcoma 1 C2 + 3 C2 + 4 C2 + Leiomyosarcoma 1 A0 - 2 A0 - 3 C2 + 4 C2 + 5 C2 + 6 C2 + Angiosarcoma 1 C2 + 3 C2 + Malignant fibrous histiocytoma 1 C2 + 2 A0 - 4 C2 + 5 B2 + Liposarcoma 1 C2 + 2 A0 - 5 C2 + 6 A2 + Chondrosarcoma 1 C2 + aW6/32 scoring based on intensity (score from 0 to 3) and percentage of positive cells (A: <25% positive cells, B: 25-75% positive cells, C: >75% positive cells). bCases were considered negative if the immunohistochemical staining had a score of 0 to 1 in less than or equal to 25% tumor cells (A0 or A1). All other cases were considered positive.
Volume 4, Issue 1
